Arrowstreet Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Arrowstreet Capital’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,700	Closed	-$280K	–	2297
2021 Q1	$280K	Sell	6,700 -9,400	-58%	-$436K	﹤0.01%	2101
2020 Q4	$750K	Buy	+16,100	New	+$753K	﹤0.01%	1901
2020 Q3	–	Sell	-13,813	Closed	-$663K	–	2568
2020 Q2	$663K	Buy	13,813 +100	+0.7%	+$4.99K	﹤0.01%	1903
2020 Q1	$631K	Sell	13,713 -13,414	-49%	-$673K	﹤0.01%	1462
2019 Q4	$1.63M	Buy	+27,127	New	+$1.62M	﹤0.01%	1198
2018 Q3	–	Sell	-4,030	Closed	-$305K	–	1296
2018 Q2	$305K	Sell	4,030 -4,318	-52%	-$272K	﹤0.01%	969
2018 Q1	$440K	Sell	8,348 -167,838	-95%	-$9.76M	﹤0.01%	969
2017 Q4	$9.41M	Sell	176,186 -39,809	-18%	-$2.22M	0.02%	459
2017 Q3	$12.9M	Buy	215,995 +212,495	+6,071%	+$12.9M	0.03%	340
2017 Q2	$276K	Buy	+3,500	New	+$286K	﹤0.01%	959

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital's EGRX Position: Q2 2021 in Review

Arrowstreet Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2021, closing a stake of 6,700 shares — an estimated $280K sold.

Arrowstreet Capital first reported a position in EGRX in Q2 2017 and held it in 10 quarters. The position peaked at $12.9M in Q3 2017. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

Arrowstreet Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Arrowstreet Capital sold 6,700 Eagle Pharmaceuticals, Inc. shares in Q2 2021, an estimated $280K.
Arrowstreet Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 10 quarters.
Arrowstreet Capital's Eagle Pharmaceuticals, Inc. position peaked at $12.9M in Q3 2017.
146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on Arrowstreet Capital's 13F filing for Q2 2021, filed 13 Aug 2021.